1
|
Shuleta-Qehaja S, Kapedanovska Nestorovska A, Naumovska Z, Stefanovski P, Dimovski A, Sterjev Z, Shuturkova L. CYP2D6 polymorphisms and the therapeutic outcome with Tamoxifen therapy in breast cancer patients from Kosovo. MAKEDONSKO FARMACEVTSKI BILTEN 2019. [DOI: 10.33320/maced.pharm.bull.2018.64.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Tamoxifen is a selective estrogen receptor modulator (SERM) used for the prevention of breast cancer and for the treatment of metastatic and early stage receptor positive breast cancer. It has been shown than tamoxifen is metabolized by the cytochrome P450 2D6 (CYP2D6) enzymes, especially with the CYP26 isoform. The aim of this study was to examine the prevalence of CYP2D6*4, CYP2D6*9 and CYP2D6*10 variants in patients with breast cancer in Kosovo as well as the association between CYP2D6 polymorphisms and the therapeutic outcome in tamoxifen treated patients. The study included 111 patients who were at the age of 25 to 70 years (45.75 ± 9.50). The overall variant allele frequency of CYP2D6*4 was 0.16. The genotypic frequencies of the CYP2D6*4 polymorphism in all patients were 0.02 for *4/*4, 0.28 for *1/*4 and 0.70 for the *1/*1 genotype. The overall CYP2D6*10 variant allele frequency was 0.30 and the frequency of *10/*10, *1/*10 and *1/*1 genotypes was 0.11, 0.37 and 0.52, respectively. In our study, a population of the CYP2D6∗9 variant allele was not detected. In addition, we did not find any correlation between the evaluated genotypes for CYP2D6 polymorphisms and the therapeutic outcome with tamoxifen therapy. Although our study is a rather small- scale compared to large multicentre studies, we believe that it will contribute to determining the impact of CYP2D6 polymorphisms on the success of tamoxifen therapy in patients with a diagnosed breast cancer. Our results are pointing to the direction of the growing number of claims that there is still no strong evidence of any therapeutic connection between the polymorphisms examined and the outcome of the therapy.
Keywords: Tamoxifen, breast cancer, CY2D6*4, CYP2D6*9, CYP2D6*10
Collapse
Affiliation(s)
| | | | - Zorica Naumovska
- Ss Cyril and Methodius University, Faculty of Pharmacy, Majka Tereza 47, Skopje, Republic of Macedonia
| | - Petar Stefanovski
- Clinical Hospital Dr. Trifun Panovski, Department of Oncology, ASNOM n.n., Bitola, Republic of Macedonia
| | - Aleksandar Dimovski
- Ss Cyril and Methodius University, Faculty of Pharmacy, Majka Tereza 47, Skopje, Republic of Macedonia
| | - Zoran Sterjev
- Ss Cyril and Methodius University, Faculty of Pharmacy, Majka Tereza 47, Skopje, Republic of Macedonia
| | - Ljubica Shuturkova
- Ss Cyril and Methodius University, Faculty of Pharmacy, Majka Tereza 47, Skopje, Republic of Macedonia
| |
Collapse
|
2
|
ARGALÁCSOVÁ S, SLANAŘ O, VÍTEK P, TESAŘOVÁ P, BAKHOUCHE H, DRAŽĎÁKOVÁ M, BARTOŠOVÁ O, ZIMA T, PERTUŽELKA L. Contribution of ABCB1 and CYP2D6 Genotypes to the Outcome of Tamoxifen Adjuvant Treatment in Premenopausal Women With Breast Cancer. Physiol Res 2015; 64:S539-47. [DOI: 10.33549/physiolres.933234] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Recent pre-clinical evidence suggests that the active metabolite of tamoxifen, endoxifen, is a substrate for efflux pump P-glycoprotein. The aim of our study was to evaluate, if the polymoprhisms within ABCB1 gene alter tamoxifen adjuvant treatment efficacy in premenopausal women. Totally 71 premenopausal women with estrogen receptor positive breast cancer indicated for tamoxifen adjuvant treatment were followed retrospectively for median period of 56 months. The gentic polymorphisms of CYP2D6 and ABCB1 were analyzed and potential covariates as tumor grading, staging, age at the diagnosis, comedication, quantitative positivity of ER or PR were also evaluated. Cox proportional-hazards regression model indicated that patients carrying at least one variant allele in ABCB1 rs1045642 had significantly longer time to event survival compared to wild type subjects. Non-significant trend was noted for better treatment outcome of patients carrying at least one variant allele in the SNP rs2032582, while for the CYP2D6 polymorphism poor metabolizer phenotype resulted in worse outcome in comparison to extensive metabolizers subjects with HR of 4.04 (95 % CI 0.31-52.19). Similarly, patients using CYP2D6 inhibitors had non-significantly shorter time-to-event as compared to never users resulting in hazard ratio of 2.06 (95 % CI 0.40-10.63). ABCB1 polymorphisms may affect outcome of tamoxifen adjuvant treatment in premenopausal breast cancer patiens. This factor should be taken into account in addition to the CYP2D6 polymorphism or phenotypic inhibition of CYP2D6 activity.
Collapse
Affiliation(s)
| | - O. SLANAŘ
- Institute of Pharmacology, First Faculty of Medicine, Charles University and General Teaching Hospital, Prague, Czech Republic
| | | | | | | | | | | | | | | |
Collapse
|